ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0660

Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study
Abstract Number: 0616

Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes
Abstract Number: 0471

Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)
Abstract Number: 0636

Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment
Abstract Number: 0929

Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases
Abstract Number: 0343

Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Abstract Number: 0705

Severity of SARS-CoV-2 Omicron Breakthrough Infections in Patients with Rheumatic Immune-mediated Inflammatory Diseases and Healthy Controls: Data from a Prospective Cohort Study
Abstract Number: 0097

Sex and Race/ethnicity Differences in Knee Symptoms, Function, and Radiographic Features: Preliminary Descriptive Data from the Johnston County Health Study
Abstract Number: 1101

Sex and Racial Differences in Systemic Lupus Erythematosus Among U.S. Adults in the All of Us Research Program
Abstract Number: 0434

Sex Based Differences in Cardiovascular Conditions Associated with Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Analysis of the National Inpatient Sample
Abstract Number: 1725

Sex Differences in Autoimmune Pathogenesis and Systemic Response to High Fat Diet in Lupus-prone Mice
Abstract Number: 1967

Sex Differences in Employment Outcomes in Patients with Recent Onset Rheumatoid Arthritis
Abstract Number: 0118

Sex-Based Variations in Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions
Abstract Number: 1768

Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
Abstract Number: 1742

Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].